ClinicalTrials.gg
RecruitingNCT07350018Updated Apr 28, 2026

Calfactant vs Poractant Alfa Using a Less Invasive Technique in Preterm Infants With Respiratory Distress Syndrome

A Phase 4 interventional study of Poractant alfa and Calfactant in Respiratory Distress Syndrome in Premature Infants, Respiratory Distress Syndrome (RDS) and Surfactant, sponsored by Uludag University. Recruiting at 5 sites in Turkey (Türkiye). Open to participants aged 0 Hours to 6 Hours. Per ClinicalTrials.gov, last updated 2026-04-28.

Sponsored by Uludag University · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
234
Allocation
Randomized
Ages
0 Hours to 6 Hours
Sex
All
01

Study summary

Respiratory distress syndrome (RDS) is a common cause of respiratory failure in preterm infants and is frequently treated with surfactant therapy. With the increasing use of noninvasive ventilation, less invasive methods of surfactant administration have been developed. In the technique known as Less Invasive Surfactant Administration (LISA), surfactant is delivered into the trachea through a thin catheter, without the need for endotracheal intubation. This approach may reduce lung injury and improve respiratory outcomes in spontaneously breathing preterm infants. This multicenter, prospective, randomized study aims to compare the clinical effectiveness of poractant alfa and calfactant when administered using the LISA technique in preterm infants born at less than 30 weeks' gestation with RDS who are not intubated. The study will evaluate short-term outcomes, including the need for intubation, repeat surfactant administration, and respiratory support during the first 72 hours of life, as well as longer-term outcomes such as bronchopulmonary dysplasia and other neonatal morbidities.

Read the detailed description

Respiratory distress syndrome (RDS) remains one of the leading causes of respiratory failure in preterm infants. Surfactant replacement therapy is a cornerstone of RDS management; however, traditional administration through endotracheal intubation and mechanical ventilation may contribute to ventilator-induced lung injury and increase the risk of adverse pulmonary outcomes. With the widespread adoption of non-invasive respiratory support strategies, less-invasive approaches to surfactant administration have gained increasing attention.

Less Invasive Surfactant Administration (LISA) is a technique in which surfactant is delivered directly into the trachea via a thin catheter under direct laryngoscopic visualization. At the same time, the infant continues to breathe spontaneously on noninvasive respiratory support. This method avoids endotracheal intubation and mechanical ventilation and has been associated with reduced need for invasive ventilation and improved respiratory outcomes in preterm infants.

Several surfactant preparations are currently used in neonatal practice. Poractant alfa and calfactant are two commonly administered natural surfactants with differing biochemical composition and dosing characteristics. Although both agents are widely used for the treatment of RDS, data directly comparing their effectiveness when administered via the LISA technique are limited.

This multicenter, prospective, randomized study is designed to compare the clinical efficacy of poractant alfa and calfactant administered using the LISA technique in preterm infants with respiratory distress syndrome. Eligible participants will be preterm infants born at less than 30 weeks' gestation, diagnosed with RDS based on clinical and radiographic criteria, who are spontaneously breathing and receiving noninvasive respiratory support without prior endotracheal intubation.

After enrollment, infants will be randomly assigned to receive either poractant alfa or calfactant via the LISA method. In both groups, surfactant will be administered through a thin catheter inserted into the trachea under direct laryngoscopic visualization while maintaining spontaneous breathing and noninvasive respiratory support. Standard neonatal intensive care practices will be applied throughout the study period in all participating centers.

The primary focus of the study is to compare short-term respiratory outcomes between the two treatment groups. These include the need for endotracheal intubation, the requirement for repeat surfactant administration, and the level and duration of respiratory support within the first 72 hours of life. Secondary outcomes include longer-term clinical outcomes such as the development of bronchopulmonary dysplasia at 36 weeks' postmenstrual age, as well as other neonatal morbidities, including intraventricular hemorrhage, necrotizing enterocolitis, and overall survival to discharge.

By directly comparing poractant alfa and calfactant administered via the LISA technique in a randomized, multicenter setting, this study aims to provide evidence on the optimal surfactant choice for less invasive treatment of RDS in very preterm infants. The findings are expected to inform clinical practice and contribute to the improvement of respiratory management strategies.

02

Conditions studied

  • Respiratory Distress Syndrome in Premature Infants
  • Respiratory Distress Syndrome (RDS)
  • Surfactant

Keywords

  • Respiratory Distress Syndrome
  • Premature infant
  • Poractant alfa
  • Calfactant
  • surfactant treatment
  • Less Invasive Surfactant Administration
  • LISA
03

In context

Respiratory Distress Syndrome In Premature Infants

34 studies on the registry are indexed under Respiratory Distress Syndrome In Premature Infants; 10 are open to participants now.

This study's planned enrollment of 234 is above the median of 45 across 29 interventional studies indexed under Respiratory Distress Syndrome In Premature Infants.

Browse Respiratory Distress Syndrome In Premature Infants studies →

Lead sponsor

Uludag University is the lead sponsor of 149 studies on the registry; 41 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
0 Hours to 6 Hours
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Born at a participating study center hospital.
  • Gestational age between 24 1/7 and 29 6/7 weeks (\<30 0/7 weeks).
  • Postnatal age within the first 6 hours of life.
  • Being on non-invasive respiratory support.
  • Presence of clinical and radiological findings consistent with respiratory distress syndrome (RDS).
  • Indication for surfactant therapy defined as a requirement for FiO₂ >30% to achieve target oxygen saturation (SpO₂ 90-94%) while receiving noninvasive respiratory support with a minimum pressure of 6 cmH₂O.
  • Written obtained from a parent or legal guardian.

Exclusion criteria

Exclusion Criteria:

  • Infants who were intubated for any reason before the decision to administer surfactant.
  • Severe birth asphyxia, defined as the need for advanced resuscitation after birth, 10th minute Apgar score ≤5, and arterial blood gas within the first hour of life showing pH \<7.0 and base excess (BE) ≤-12.
  • Presence of major congenital anomalies.
  • Respiratory distress due to causes other than respiratory distress syndrome (RDS).
  • Congenital heart disease.
  • Congenital diaphragmatic hernia.
  • Pulmonary hypoplasia.
  • Chromosomal abnormalities.
  • Presence of pneumothorax.
  • Lack of .
  • Neonatal seizures presence.
  • Postnatal age greater than 6 hours.
  • Infants born outside of gestational weeks 24 1/7 - 29 6/7.
  • Requirement for invasive mechanical ventilation at enrollment.
  • Infants receiving noninvasive respiratory support with an FiO₂ requirement \<0.30.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
234 participants (estimated)

Study arms

  • Active comparator
    Poractant alfa (LISA)

    Preterm infants with respiratory distress syndrome (RDS) will receive poractant alfa via the Less Invasive Surfactant Administration (LISA) technique while on noninvasive respiratory support.

    Drug: Poractant alfa

  • Active comparator
    Calfactant (LISA)

    Preterm infants with respiratory distress syndrome (RDS) will receive calfactant via the Less Invasive Surfactant Administration (LISA) technique while on noninvasive respiratory support.

    Drug: Calfactant

Interventions

  • Poractant alfa will be administered using the Less Invasive Surfactant Administration (LISA) technique. A thin catheter will be inserted into the trachea under direct laryngoscopic visualization, without the need for endotracheal intubation, while the infant continues to breathe spontaneously on noninvasive respiratory support. Dosing and administration will follow standard clinical guidelines. (200 mg/kg initial dose, 100 mg/kg repeat dose)

  • Calfactant will be administered using the Less Invasive Surfactant Administration (LISA) technique. A thin catheter will be inserted into the trachea under direct laryngoscopic visualization, without the need for endotracheal intubation, while the infant continues to breathe spontaneously on noninvasive respiratory support. Dosing and administration will follow standard clinical guidelines. (100 mg/kg initial and repeat dose)

06

What researchers measure

Primary outcomes

  1. Need for endotracheal intubation within the first 72 hours of life

    The need for endotracheal intubation within the first 72 hours of life in preterm infants born at 24 1/7-29 6/7 weeks' gestation receiving calfactant or poractant alfa via LISA.

    Time frame: Up to 72 hours after birth.

Secondary outcomes

  1. Need for Repeat Surfactant Administration

    The requirement for repeat doses of surfactant after the initial LISA procedure in preterm infants treated with calfactant or poractant alfa.

    Time frame: Up to 72 hours after birth.

  2. Adverse Events During Surfactant Administration

    The occurrence of adverse events during surfactant administration via LISA, including apnea, bradycardia, oxygen desaturation, surfactant reflux, coughing, laryngospasm, and vomiting.

    Time frame: During the surfactant administration and up to 72 hours after birth.

  3. Bronchopulmonary dysplasia

    The incidence of bronchopulmonary dysplasia at 36 weeks' postmenstrual age in preterm infants receiving calfactant or poractant alfa via LISA.

    Time frame: At 36 weeks' postmenstrual age or discharge, whichever occurred first.

  4. Retinopathy of Prematurity

    The incidence of retinopathy of prematurity (ROP) in preterm infants receiving calfactant or poractant alfa via LISA.

    Time frame: From birth until discharge, assessed up to 44 weeks' postmenstrual age.

  5. Patent Ductus Arteriosus

    The incidence of patent ductus arteriosus requiring medical or surgical treatment in preterm infants treated with calfactant or poractant alfa via LISA.

    Time frame: From birth until the date of the first documented patent ductus arteriosus requiring medical or surgical treatment or the date of hospital discharge, whichever came first, assessed up to 36 weeks' postmenstrual age.

  6. Air Leak Syndromes

    The occurrence of air leak syndromes (including pneumothorax, pulmonary interstitial emphysema, and pneumomediastinum) in preterm infants receiving calfactant or poractant alfa via LISA.

    Time frame: Up to 7 days after birth.

  7. Duration of Respiratory Support

    Total duration of invasive and noninvasive mechanical ventilation.

    Time frame: From birth until discontinuation of respiratory support or discharge, whichever occurs first. (Through study completion, an average of 1 year.)

  8. Length of Hospital Stay

    Length of hospital stay in days for preterm infants treated with calfactant or poractant alfa via LISA.

    Time frame: From birth until discharge. (Through study completion, an average of 1 year.)

  9. Mortality

    All-cause mortality before hospital discharge.

    Time frame: From the date of randomization until the date of death from any cause or the date of discharge, whichever came first. (Through study completion, an average of 1 year.)

  10. Intraventricular Hemorrhage

    The incidence of intraventricular hemorrhage (IVH) in preterm infants receiving calfactant or poractant alfa via LISA.

    Time frame: Up to the 7th day after birth.

  11. Necrotizing Enterocolitis

    The incidence of necrotizing enterocolitis (NEC) in preterm infants receiving calfactant or poractant alfa via LISA.

    Time frame: From birth until the date of the first documented necrotizing enterocolitis or the date of discharge, whichever came first, assessed up to 36 weeks' postmenstrual age.

07

Study locations

5 of 5 sites recruiting
  • Bursa City Hospital
    Bursa, Turkey (Türkiye)
    Recruiting
    • Erbu Yarcı, Associate professor · Contacterbuyarci@yahoo.com · +90 505 729 3482
    • Erbu Yarcı, Associate professor · Principal investigator
    • Bayram Ali Dorum, Associate professor · Sub investigator
    • Birgül Mutlu, Neonatologist · Sub investigator
    • Betül Türen, Pediatrician · Sub investigator
  • Division of Neonatology, Department of Pediatrics, Bursa Uludağ University Faculty of Medicine
    Bursa, Turkey (Türkiye)
    Recruiting
    • Salih Çağrı Çakır, Associate professor · Contactsalihcagri@uludag.edu.tr · +90 533 3453739
    • Fatma Nirgül Köksal, Professor · Sub investigator
    • Hilal Özkan, Professor · Sub investigator
    • Cansu Sivrikaya Yıldırım, Neonatologist · Sub investigator
    • Funda Aydemir, Pediatrician · Sub investigator
    • Enes İn, Pediatrician · Sub investigator
    • Salih Çağrı Çakır, Associate professor · Principal investigator
  • Division of Neonatology, Department of Pediatrics, University of Health Sciences Bursa Yuksek İhtisas Training and Research Hospital
    Bursa, Turkey (Türkiye)
    Recruiting
    • İpek Güney Varal, Professor · Contactipekguneyvaral@gmail.com · +90 532 3413389
    • İpek Güney Varal, Professor · Principal investigator
    • Gaffari Tunç, Associate professor · Sub investigator
    • Onur Bağcı, Neonatologist · Sub investigator
    • Aybüke Yazıcı, Associate professor · Sub investigator
    • Ayşe Ören, Pediatrician · Sub investigator
  • Dörtçelik Children's Diseases Hospital
    Bursa, Turkey (Türkiye)
    Recruiting
    • Fatma Kocael, Neonatologist · Contactfatma.irioglu@gmail.com · +90 505 678 6875
    • Fatma İrioğlu, Neonatologist · Principal investigator
    • Kevser Elmas Üstün, Neonatologist · Sub investigator
  • Medicana Bursa Hospital
    Bursa, Turkey (Türkiye)
    Recruiting
    • Şerif Hamitoğlu · Contactdrserif@gmail.com · +90 555 5541694
    • Şerif Hamitoğlu · Principal investigator
08

References and documents

Publications

  • Kakkilaya V, Gautham KS. Should less invasive surfactant administration (LISA) become routine practice in US neonatal units? Pediatr Res. 2023 Apr;93(5):1188-1198. doi: 10.1038/s41390-022-02265-8. Epub 2022 Aug 19. PubMed 35986148 ↗
  • Sweet DG, Carnielli VP, Greisen G, Hallman M, Klebermass-Schrehof K, Ozek E, Te Pas A, Plavka R, Roehr CC, Saugstad OD, Simeoni U, Speer CP, Vento M, Visser GHA, Halliday HL. European Consensus Guidelines on the Management of Respiratory Distress Syndrome: 2022 Update. Neonatology. 2023;120(1):3-23. doi: 10.1159/000528914. Epub 2023 Feb 15. PubMed 36863329 ↗

Individual participant data

Plan to share: No — I am not authorized to share patient data.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2026 (actual). Primary completion is estimated for Feb 2027, 13 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2026
First posted
Jan 20, 2026
StartActual
Jan 20, 2026
Primary completionEst.
Feb 20, 2027
CompletionEst.
Feb 20, 2027
Last update
Apr 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07350018
Lead sponsor
Uludag University
Responsible party
Salih Çağrı Çakır (Associate professor, Uludag University) — Principal investigator
First posted
Jan 20, 2026
Start date
Jan 20, 2026
Primary completion
Feb 20, 2027 (estimated)
Completion
Feb 20, 2027 (estimated)
Last update
Apr 28, 2026

Study contacts

Salih Çağrı Çakır, Associate professor
Contact
salihcagri@uludag.edu.tr
+90 533 3453739

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Poractant alfa · Calfactant

Start the discussion